Advertisement
Australia markets closed
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     
  • AUD/USD

    0.6492
    +0.0003 (+0.05%)
     
  • OIL

    82.80
    -0.56 (-0.67%)
     
  • GOLD

    2,334.80
    -7.30 (-0.31%)
     
  • Bitcoin AUD

    99,630.35
    -3,187.26 (-3.10%)
     
  • CMC Crypto 200

    1,397.83
    -26.27 (-1.84%)
     
  • AUD/EUR

    0.6071
    +0.0015 (+0.25%)
     
  • AUD/NZD

    1.0950
    +0.0020 (+0.18%)
     
  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     
  • NASDAQ

    17,497.22
    +25.75 (+0.15%)
     
  • FTSE

    8,040.38
    -4.43 (-0.06%)
     
  • Dow Jones

    38,460.45
    -43.24 (-0.11%)
     
  • DAX

    18,088.70
    -48.95 (-0.27%)
     
  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

Is This Pharma Duo on the Brink of Another Billion-Dollar Opportunity?

Is This Pharma Duo on the Brink of Another Billion-Dollar Opportunity?

On March 23, Sanofi (NASDAQ: SNY) and Regeneron's (NASDAQ: REGN) Dupixent shared positive results in its phase 3 clinical trial of patients with uncontrolled, chronic obstructive pulmonary disease (COPD). Let's take a look at the clinical data and the global COPD market to assess the sales potential of the drug.